Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells

Journal of Virology

Volumn 77, Issue 9, 2003, Pages 5218-5225

  Guebre Xabier, Mimi ^a   Hammond, Scott A ^a   Epperson, Diane E ^a   Yu, Jianmei ^a   Ellingsworth, Larry ^a   Glenn, Gregory M ^a  

^a IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROTOXIN; GAMMA INTERFERON; HEAT LABILE ENTEROTOXIN; IMMUNOGLOBULIN A; IMMUNOSTIMULATING AGENT; INTERLEUKIN 4; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; CELL ISOLATION; CELL MIGRATION; DENDRITIC CELL; DRAIN; ESCHERICHIA COLI; FEMALE; HEMAGGLUTINATION; HYPOTHESIS; IMMUNE RESPONSE; INFLUENZA VIRUS; LUNG; LYMPH NODE; MOUSE; MUCOSA; NONHUMAN; OBSERVATION; PATCH DYNAMICS; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN-PRESENTING CELLS; BACTERIAL TOXINS; DENDRITIC CELLS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNIZATION; INFLUENZA VACCINES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; SKIN; T-LYMPHOCYTES;

EID: 0037405186     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.9.5218-5225.2003     Document Type: Article

References (35)

1. Arrington, J., R. P. Braun, L. Dong, D. H. Fuller, M. D. Macklin, S. W. Umlauf, S. J. Wagner, M. S. Wu, L. G. Payne, and J. R. Haynes. 2002. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76:4536-4546.
2. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
3. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-787.
4. high murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165:49-58.
5. Davies, J. R., and E. A. Grilli. 1989. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. Infect. 102:325-333.
6. de Bruijn, I. A., E. J. Remarque, C. M. Jol-van der Zijde, M. J. van Tol, R. G. Westendorp, and D. L. Knook. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179:31-36.
7. El-Ghorr, A. A., R. M. Williams, C. Heap, and M. Norval. 2000. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29:255-261.
8. Enioutina, E. Y., D. Visic, and R. A. Daynes. 2000. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18:2753-2767.
9. Gasparini, R., T. Pozzi, E. Montomoli, E. Fragapane, F. Senatore, M. Minutello, and A. Podda. 2001. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17:135-140.
10. Glenn, G. M., D. Lang, and D. Taylor. 2000. Transcutaneous immunization, p. 91-93. In M. A. Gerber (ed.), The Jordan report 2000: accelerated development of vaccines. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
11. Glenn, G. M., T. Scharton-Kersten, R. Vassell, C. P. Mailett, T. L. Hale, and C. R. Alving. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
12. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406.
13. Graham, B. S., M. C. Keefer, M. J. McElrath, G. J. Gorse, D. H. Schwartz, K. Weinhold, T. J. Matthews, J. R. Esterlitz, F. Sinangil, P. E. Fast, et al. 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann. Intern. Med. 125:270-279.
14. Greenbaum, E., A. Furst, A. Kiderman, B. Stewart, R. Levy, M. Schlesinger, A. Morag, and Z. Zakay-Rones. 2001. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J. Med. Virol. 65:178-184.
15. Guerena-Burgueno, F., E. R. Hall, D. N. Taylor, F. J. Cassels, D. A. Scott, M. K. Wolf, Z. J. Roberts, G. V. Nesterova, C. R. Alving, and G. M. Glenn. 2002. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70:1874-1880.
16. Halperin, S. A., B. Smith, T. Mabrouk, M. Germain, P. Trepanier, T. Hassell, J. Treanor, R. Gauthier, and E. L. Mills. 2002. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247.
17. Hammond, S. A., M. Guebre-Xabier, J. Yu, and G. M. Glenn. 2001. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit. Rev. Ther. Drug Carrier Sys. 18:503-526.
18. Hammond, S. A., D. Walwender, C. R. Alving, and G. M. Glenn. 2001. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 19:2701-2707.
19. Hirota, Y., M. Kaji, S. Ide, J. Kajiwara, K. Kataoka, S. Goto, and T. Oka. 1997. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 15:962-967.
20. Jakob, T., and M. C. Udey. 1999. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv. Dermatol. 14:209-258.
21. Johnston, L. J., G. M. Halliday, and N. J. King. 2000. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Investig. Dermatol. 114:560-568.
22. Kripke, M. L., C. G. Munn, A. Jeevan, J. M. Tang, and C. Bucana. 1990. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145:2833-2838.
23. Macatonia, S. E., S. C. Knight, A. J. Edwards, S. Griffiths, and P. Fryer. 1987. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J. Exp. Med. 166:1654-1667.
24. Martin, J. T. 1997. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 25:209-213.
25. Martinez, F. D. 2001. The coming-of-age of the hygiene hypothesis. Respir. Res. 2:129-132.
26. Michetti, P., C. Kreiss, K. L. Kotloff, N. Porta, J. L. Blanco, D. Bachmann, M. Herranz, P. F. Saldinger, I. Corthesy-Theulaz, G. Losonsky, R. Nichols, J. Simon, M. Stolte, S. Ackerman, T. P. Monath, and A. L. Blum. 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804-812.
27. Moreln, B., K. Lovgren-Bengtsson, and J. Cox. 1996. Modern adjuvants, functional aspects, p. 243-263. In S. H. E. Kaufmann (ed.), Concepts in vaccine development. Walter de Gruyter, Berlin, Germany.
28. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
29. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20:1412-1420.
30. Rescigno, M., S. Citterio, C. Thery, M. Rittig, D. Medaglini, G. Pozzi, S. Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc. Natl. Acad. Sci. USA 95:5229-5234.
31. Salk, J. E., M. Contakos, A. M. Laurent, M. Sorensen, A. J. Rapalski, H. Simmons, and H. Sandberg. 1953. Use of adjuvants in studies on influenza immunization. Degree of persistence of antibody in human subjects two years after vaccination. JAMA 151:1169-1175.
32. Scharton-Kersten, T., J. Yu, R. Vassell, D. O'Hagan, C. R. Alving, and G. M. Glenn. 2000. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:5306-5313.
33. Singh, M., and D. O'Hagan. 1999. Advances in vaccine adjuvants. Nat. Biotechnol. 17:1075-1081.
34. Udey, M. C. 1997. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 10(Suppl. 1):6-8.
35. Yu, J., F. Cassels, T. Scharton-Kersten, S. A. Hammond, A. Hartman, E. Angov, B. Corthesy, C. Alving, and G. Glenn. 2002. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70:1056-1068.